Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 476

1.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM.

Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.

2.

Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy.

Haynes BP, Ginsburg O, Gao Q, Folkerd E, Afentakis M, Quang LH, Han PT, Khoa PH, Dinh NV, To TV, Clemons M, Smith IE, Dowsett M.

NPJ Breast Cancer. 2017 Nov 27;3:47. doi: 10.1038/s41523-017-0049-z. eCollection 2017.

3.

De-escalating and escalating systemic therapy of early breast cancer.

Smith IE, Okines AFC.

Breast. 2017 Aug;34 Suppl 1:S5-S9. doi: 10.1016/j.breast.2017.06.019. Epub 2017 Jul 8. No abstract available.

PMID:
28694014
4.

Reply to R. Goncalves et al.

Smith IE.

J Clin Oncol. 2017 Aug 10;35(23):2719. doi: 10.1200/JCO.2017.73.2214. Epub 2017 Jun 5. No abstract available.

PMID:
28581885
5.

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.

Sheri A, Smith IE, Hills M, Jones RL, Johnston SR, Dowsett M.

Breast Cancer Res Treat. 2017 Jul;164(2):395-400. doi: 10.1007/s10549-017-4266-9. Epub 2017 Apr 26.

6.

Hospital outcomes and long-term survival after referral to a specialized weaning unit.

Davies MG, Quinnell TG, Oscroft NS, Clutterbuck SP, Shneerson JM, Smith IE.

Br J Anaesth. 2017 Apr 1;118(4):563-569. doi: 10.1093/bja/aex031.

7.

Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.

Detre SI, Ashley S, Mohammed K, Smith IE, Powles TJ, Dowsett M.

Cancer Prev Res (Phila). 2017 Mar;10(3):171-176. doi: 10.1158/1940-6207.CAPR-16-0247-T. Epub 2017 Jan 18.

8.

Research needs in breast cancer.

Cardoso F, Harbeck N, Barrios CH, Bergh J, Cortés J, El Saghir N, Francis PA, Hudis CA, Ohno S, Partridge AH, Sledge GW, Smith IE, Gelmon KA.

Ann Oncol. 2017 Feb 1;28(2):208-217. doi: 10.1093/annonc/mdw571.

PMID:
27831505
9.

Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease.

Klintman M, Buus R, Cheang MC, Sheri A, Smith IE, Dowsett M.

Clin Cancer Res. 2016 May 15;22(10):2405-16. doi: 10.1158/1078-0432.CCR-15-1488.

10.

Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab.

Kordbacheh T, Law WY, Smith IE.

Breast. 2016 Apr;26:54-8. doi: 10.1016/j.breast.2015.11.005. Epub 2016 Jan 22. Review.

PMID:
27017242
11.

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Eur J Cancer. 2016 Mar;56:85-92. doi: 10.1016/j.ejca.2015.12.024. Epub 2016 Jan 30.

PMID:
26829011
12.

Characterization and quantification of suspended sediment sources to the Manawatu River, New Zealand.

Vale SS, Fuller IC, Procter JN, Basher LR, Smith IE.

Sci Total Environ. 2016 Feb 1;543(Pt A):171-86. doi: 10.1016/j.scitotenv.2015.11.003. Epub 2015 Nov 12.

PMID:
26580740
13.

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, Nerurkar A, Osin P, Chandarlapaty S, Martin LA, Dowsett M, Smith IE, Turner NC.

Sci Transl Med. 2015 Nov 11;7(313):313ra182. doi: 10.1126/scitranslmed.aac7551.

14.

Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab.

Yeo B, Kotsori K, Mohammed K, Walsh G, Smith IE.

Breast. 2015 Dec;24(6):751-7. doi: 10.1016/j.breast.2015.09.008. Epub 2015 Oct 9.

PMID:
26456898
15.

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC.

Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021.

PMID:
26311728
16.

Management of breast cancer in older and frail patients.

Smith IE, Fribbens C.

Breast. 2015 Nov;24 Suppl 2:S159-62. doi: 10.1016/j.breast.2015.07.037. Epub 2015 Aug 21.

PMID:
26303987
17.

Catalytic in vivo protein knockdown by small-molecule PROTACs.

Bondeson DP, Mares A, Smith IE, Ko E, Campos S, Miah AH, Mulholland KE, Routly N, Buckley DL, Gustafson JL, Zinn N, Grandi P, Shimamura S, Bergamini G, Faelth-Savitski M, Bantscheff M, Cox C, Gordon DA, Willard RR, Flanagan JJ, Casillas LN, Votta BJ, den Besten W, Famm K, Kruidenier L, Carter PS, Harling JD, Churcher I, Crews CM.

Nat Chem Biol. 2015 Aug;11(8):611-7. doi: 10.1038/nchembio.1858. Epub 2015 Jun 10.

18.

HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.

Buckley DL, Raina K, Darricarrere N, Hines J, Gustafson JL, Smith IE, Miah AH, Harling JD, Crews CM.

ACS Chem Biol. 2015 Aug 21;10(8):1831-7. doi: 10.1021/acschembio.5b00442. Epub 2015 Jun 23.

19.

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Breast Cancer Res. 2015 Apr 16;17:56. doi: 10.1186/s13058-015-0568-1.

20.

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.

Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE; TEACH Investigators.

Eur J Cancer. 2015 Apr;51(6):685-96. doi: 10.1016/j.ejca.2015.02.005. Epub 2015 Mar 6.

PMID:
25752740
21.

Reply to C. Twelves et Al.

Partridge AH, Rumble RB, Smith IE.

J Clin Oncol. 2015 Apr 10;33(11):1301. doi: 10.1200/JCO.2014.60.2508. Epub 2015 Mar 2. No abstract available.

PMID:
25732166
22.

Erratum to: Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer.

Haynes BP, Viale G, Galimberti V, Rotmensz N, Gibelli B, Smith IE, Dowsett M.

Breast Cancer Res Treat. 2015 Jan;149(1):311. doi: 10.1007/s10549-014-3210-5. No abstract available.

PMID:
25425349
23.

Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer.

Haynes BP, Viale G, Galimberti V, Rotmensz N, Gibelli B, Smith IE, Dowsett M.

Breast Cancer Res Treat. 2014 Nov;148(2):327-35. doi: 10.1007/s10549-014-3181-6. Epub 2014 Nov 4. Erratum in: Breast Cancer Res Treat. 2015 Jan;149(1):311.

PMID:
25367875
24.

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.

Sheri A, Smith IE, Johnston SR, A'Hern R, Nerurkar A, Jones RL, Hills M, Detre S, Pinder SE, Symmans WF, Dowsett M.

Ann Oncol. 2015 Jan;26(1):75-80. doi: 10.1093/annonc/mdu508. Epub 2014 Oct 30.

PMID:
25361988
25.

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE.

J Clin Oncol. 2014 Oct 10;32(29):3307-29. doi: 10.1200/JCO.2014.56.7479. Epub 2014 Sep 2.

26.

Volume assured versus pressure preset non-invasive ventilation for compensated ventilatory failure in COPD.

Oscroft NS, Chadwick R, Davies MG, Quinnell TG, Smith IE.

Respir Med. 2014 Oct;108(10):1508-15. doi: 10.1016/j.rmed.2014.07.010. Epub 2014 Jul 23.

27.

Pre-flight assessment in patients with obesity hypoventilation syndrome.

Ali M, Smith IE, Gulati A, Shneerson JM.

Respirology. 2014 Nov;19(8):1229-32. doi: 10.1111/resp.12353. Epub 2014 Jul 23.

28.

A crossover randomised controlled trial of oral mandibular advancement devices for obstructive sleep apnoea-hypopnoea (TOMADO).

Quinnell TG, Bennett M, Jordan J, Clutterbuck-James AL, Davies MG, Smith IE, Oscroft N, Pittman MA, Cameron M, Chadwick R, Morrell MJ, Glover MJ, Fox-Rushby JA, Sharples LD.

Thorax. 2014 Oct;69(10):938-45. doi: 10.1136/thoraxjnl-2014-205464. Epub 2014 Jul 17.

PMID:
25035126
29.

Status of adjuvant endocrine therapy for breast cancer.

Schiavon G, Smith IE.

Breast Cancer Res. 2014;16(2):206. Review.

30.

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM.

J Clin Oncol. 2014 Jul 10;32(20):2159-65. doi: 10.1200/JCO.2013.53.9288. Epub 2014 Jun 9.

PMID:
24912899
31.

Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy.

Alder CM, Ambler M, Campbell AJ, Champigny AC, Deakin AM, Harling JD, Harris CA, Longstaff T, Lynn S, Maxwell AC, Mooney CJ, Scullion C, Singh OM, Smith IE, Somers DO, Tame CJ, Wayne G, Wilson C, Woolven JM.

ACS Med Chem Lett. 2013 Aug 12;4(10):948-52. doi: 10.1021/ml400206q. eCollection 2013 Oct 10.

32.

The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?

Smith IE, Yeo B, Schiavon G.

Am Soc Clin Oncol Educ Book. 2014:e16-24. doi: 10.14694/EdBook_AM.2014.34.e16. Review.

33.

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.

Arnedos M, Drury S, Afentakis M, A'Hern R, Hills M, Salter J, Smith IE, Reis-Filho JS, Dowsett M.

Ann Oncol. 2014 Mar;25(3):605-10. doi: 10.1093/annonc/mdt575. Epub 2014 Feb 12.

34.

Follow-up tests to detect recurrent disease: patient's reassurance or medical need?

Smith IE, Schiavon G.

Breast. 2013 Aug;22 Suppl 2:S156-60. doi: 10.1016/j.breast.2013.07.030. Review.

PMID:
24074779
35.

Endocrine therapy for advanced/metastatic breast cancer.

Schiavon G, Smith IE.

Hematol Oncol Clin North Am. 2013 Aug;27(4):715-36, viii. doi: 10.1016/j.hoc.2013.05.004. Epub 2013 Jun 18. Review.

PMID:
23915741
36.

Noninvasive detection of HER2 amplification with plasma DNA digital PCR.

Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, Smith IE, Ashworth A, Turner NC.

Clin Cancer Res. 2013 Jun 15;19(12):3276-84. doi: 10.1158/1078-0432.CCR-12-3768. Epub 2013 May 1.

37.

Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.

Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P, A'hern R, Miller WR, Smith IE, Dowsett M.

Clin Cancer Res. 2013 May 15;19(10):2775-86. doi: 10.1158/1078-0432.CCR-12-1000. Epub 2013 Mar 14.

38.

Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer.

Haynes BP, Viale G, Galimberti V, Rotmensz N, Gibelli B, A'Hern R, Smith IE, Dowsett M.

Breast Cancer Res Treat. 2013 Feb;138(1):157-65. doi: 10.1007/s10549-013-2426-0. Epub 2013 Feb 3.

PMID:
23378065
39.

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM; TEACH investigators.

Lancet Oncol. 2013 Jan;14(1):88-96. doi: 10.1016/S1470-2045(12)70508-9. Epub 2012 Dec 10. Erratum in: Lancet Oncol. 2013 Feb;14(2):e47.

PMID:
23234763
40.

A solitary bone lesion in a patient with previous breast cancer and the importance of bone biopsy: a case report and a review of guidelines.

Schiavon G, Tait DM, Briggs TW, Smith IE.

Clin Breast Cancer. 2013 Feb;13(1):77-80. doi: 10.1016/j.clbc.2012.10.004. Epub 2012 Nov 29. No abstract available.

PMID:
23199805
41.

Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.

Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Thürlimann B, Bonnefoi H, Forbes JF, Paridaens RJ, Rabaglio M, Gelber RD, Colleoni M, Láng I, Smith IE, Coates AS, Goldhirsch A, Mouridsen HT.

J Clin Oncol. 2012 Nov 10;30(32):3967-75. doi: 10.1200/JCO.2011.40.8666. Epub 2012 Oct 8.

42.

Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes.

Wong M, O'Neill S, Walsh G, Smith IE.

Ann Oncol. 2013 Jan;24(1):133-8. doi: 10.1093/annonc/mds250. Epub 2012 Sep 27.

PMID:
23019276
43.

Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.

Borthwick AD, Liddle J, Davies DE, Exall AM, Hamlett C, Hickey DM, Mason AM, Smith IE, Nerozzi F, Peace S, Pollard D, Sollis SL, Allen MJ, Woollard PM, Pullen MA, Westfall TD, Stanislaus DJ.

J Med Chem. 2012 Jan 26;55(2):783-96. doi: 10.1021/jm201287w. Epub 2012 Jan 12.

PMID:
22239250
44.

Direct preparation of thiazoles, imidazoles, imidazopyridines and thiazolidines from alkenes.

Donohoe TJ, Kabeshov MA, Rathi AH, Smith IE.

Org Biomol Chem. 2012 Feb 7;10(5):1093-101. doi: 10.1039/c1ob06587d. Epub 2011 Dec 12.

PMID:
22159268
45.

UK guidance document: treatment of metastatic breast cancer.

Coleman RE, Bertelli G, Beaumont T, Kunkler I, Miles D, Simmonds PD, Jones AL, Smith IE.

Clin Oncol (R Coll Radiol). 2012 Apr;24(3):169-76. doi: 10.1016/j.clon.2011.10.004. Epub 2011 Nov 8.

PMID:
22075442
46.

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF; International Ki-67 in Breast Cancer Working Group.

J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64. doi: 10.1093/jnci/djr393. Epub 2011 Sep 29.

47.

Obstructive sleep apnoea: relevance to non-sleep clinicians.

Smith IE, Quinnell TG.

Clin Med (Lond). 2011 Jun;11(3):286-9. Review. No abstract available.

PMID:
21902088
48.

Narcolepsy, idiopathic hypersomnolence and related conditions.

Quinnell TG, Smith IE.

Clin Med (Lond). 2011 Jun;11(3):282-6. No abstract available.

PMID:
21902087
49.

Presurgical progesterone in early breast cancer: so much for so little?

Dowsett M, Smith IE.

J Clin Oncol. 2011 Jul 20;29(21):2839-41. doi: 10.1200/JCO.2011.36.1295. Epub 2011 Jun 13. No abstract available.

PMID:
21670461
50.

The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy.

Barton SR, Smith IE, Kirby AM, Ashley S, Walsh G, Parton M.

Eur J Cancer. 2011 Sep;47(14):2099-106. doi: 10.1016/j.ejca.2011.05.010. Epub 2011 Jun 12.

PMID:
21658935

Supplemental Content

Loading ...
Support Center